Background: Zanamivir, a neuraminidase inhibitor, reduces the number of days of illness in influenza-positive patients …. New bedside rapid flu tests (RFT) should increase the number of influenza-positive patients whom receive zanamivir … appropriately. Objective: To estimate the economic effects of implementing RFT and zanamivir among unvaccinated healthy working …

Objective: To evaluate the cost effectiveness of zanamivir 10mg twice daily for 5 days in the treatment of influenza in … clinical trials. Patients: A total of 154 zanamivir and 167 placebo high-risk patients were included in the analysis. Main …-effectiveness acceptability curves demonstrated 90% certainty that zanamivir would be cost effective at Lstg 8000 per QALY. Conclusions …

Objective: This study examined the impact of zanamivir treatment on patient morbidity in patients with influenza … virologically confirmed influenza. Interventions: Two different zanamivir treatment regimens [twice daily (bid) or 4 times daily … zanamivir had additional contacts with healthcare professionals compared with those who received placebo (8 vs 14%; p <= 0 …

Objective: To use data from a clinical trial of zanamivir, a new antiviral drug, to estimate the costs and …. Cost data were used to translate the clinical data into treatment cost estimates. Results: Treatment with zanamivir for … the influenza-positive rate and the impact of zanamivir on days to alleviate symptoms and hospitalisation. Conclusions …